EP
SGMO

Elkfork Partners’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Elkfork Partners’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$12K Hold
1,320
– – ﹤0.01% 1045
2019
Q2 		$14K Buy
+1,320
New +$14K ﹤0.01% 1040
2019
Q1 		– Sell
-17,710
Closed -$203K – 1045
2018
Q4 		$203K Sell
17,710
-7,766
-30% -$96.5K 0.01% 759
2018
Q3 		$432K Buy
25,476
+12,232
+92% +$186K 0.01% 638
2018
Q2 		$188K Buy
13,244
+9,944
+301% +$165K ﹤0.01% 812
2018
Q1 		$63K Buy
+3,300
New +$70.5K ﹤0.01% 984

Other funds holding SGMO

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Elkfork Partners's SGMO Position: Q3 2019 in Review

Elkfork Partners held its SANGAMO THERAPEUTICS INC (SGMO) position steady in Q3 2019 at 1,320 shares worth $12K. The position accounts for ﹤0.01% of the portfolio, ranked #1045.

Elkfork Partners first reported a position in SGMO in Q1 2018 and has held it in 6 quarters since. The position peaked at $432K in Q3 2018. 184 funds tracked by Wall St. Rank hold SGMO as of Q3 2019.

  • Elkfork Partners held 1,320 shares of SANGAMO THERAPEUTICS INC worth $12K as of Q3 2019.
  • Elkfork Partners left its SANGAMO THERAPEUTICS INC share count unchanged in Q3 2019.
  • SANGAMO THERAPEUTICS INC made up ﹤0.01% of Elkfork Partners's portfolio in Q3 2019, its #1045 holding.
  • Elkfork Partners first reported a position in SANGAMO THERAPEUTICS INC in Q1 2018 and has held it in 6 quarters since.
  • Elkfork Partners's SANGAMO THERAPEUTICS INC position peaked at $432K in Q3 2018.
  • 184 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q3 2019.

Based on Elkfork Partners's 13F filing for Q3 2019, filed 14 Nov 2019.